Quarterly report [Sections 13 or 15(d)]

SEGMENT INFORMATION (Details)

v3.25.3
SEGMENT INFORMATION (Details) - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Segment Reporting Information [Line Items]        
Number of segments     1  
Total revenues $ 69,462,000 $ 55,307,000 $ 224,480,000 $ 121,682,000
Less:        
Cost of product sales 4,753,000 8,026,000 13,666,000 12,858,000
(Benefit from) provision for income taxes (280,000) 0 154,000 0
Net income 27,900,000 12,421,000 98,959,000 3,144,000
Single reportable segment        
Segment Reporting Information [Line Items]        
Total revenues 69,462,000 55,307,000 224,480,000 121,682,000
Less:        
Employee related expenses 18,547,000 16,104,000 56,666,000 52,552,000
Commercial related expenses 6,303,000 6,768,000 18,915,000 19,002,000
Outside clinical trial related expenses 3,759,000 3,303,000 11,362,000 8,183,000
Cost of product sales 4,753,000 8,026,000 13,666,000 12,859,000
Consultants and third-party services 4,133,000 3,476,000 10,751,000 11,851,000
Other segment items 3,547,000 3,574,000 10,824,000 9,698,000
Interest expense, net 800,000 1,635,000 3,183,000 4,393,000
(Benefit from) provision for income taxes (280,000)   154,000  
Net income $ 27,900,000 $ 12,421,000 $ 98,959,000 $ 3,144,000